Ravidasvir

{{Short description|Chemical compound}}

{{Use dmy dates|date=June 2019}}

{{Drugbox

| Verifiedfields =

| Watchedfields =

| verifiedrevid =

| IUPAC_name = (2S)-2-{[Hydroxy(methoxy)methylidene]amino}-1-[(2S)-2-[5-(6-{2-[(2S)-1-[(2S)-2-{[hydroxy(methoxy)methylidene]amino}-3-methylbutanoyl]pyrrolidin-2-yl]-1H-1,3-benzodiazol-6-yl}naphthalen-2-yl)-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methylbutan-1-one

| image = Ravidasvir.svg

| image_class = skin-invert-image

| width = 275

| tradename =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number_Ref =

| CAS_number = 1242087-93-9

| ATC_prefix = J05

| ATC_suffix = AP13

| PubChem = 52918888

| DrugBank_Ref =

| DrugBank =

| KEGG = D12744

| ChemSpiderID = 31141686

| ChEMBL = 3121849

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = AL3G001BI8

| synonyms = PPI-668

| C=42 | H=50 | N=8 | O=6

| molecular_weight =

| smiles = CC(C)[C@@H](C(=O)N1CCC[C@H]1C2=NC3=C(N2)C=C(C=C3)C4=CC5=C(C=C4)C=C(C=C5)C6=CN=C(N6)[C@@H]7CCCN7C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC

| StdInChI = 1S/C42H50N8O6/c1-23(2)35(47-41(53)55-5)39(51)49-17-7-9-33(49)37-43-22-32(46-37)29-14-13-25-19-26(11-12-27(25)20-29)28-15-16-30-31(21-28)45-38(44-30)34-10-8-18-50(34)40(52)36(24(3)4)48-42(54)56-6/h11-16,19-24,33-36H,7-10,17-18H2,1-6H3,(H,43,46)(H,44,45)(H,47,53)(H,48,54)/t33-,34-,35-,36-/m0/s1

| StdInChIKey = LCHMHYPWGWYXEL-ZYADHFCISA-N

}}

Ravidasvir (PPI-668) is an investigational NS5A inhibitor (by Pharco Pharmaceuticals) in clinical trials for chronic hepatitis C genotype 4.{{ClinicalTrialsGov|NCT02371408|Study of the Efficacy and Safety of PPI-668 (NS5A Inhibitor) Plus Sofosbuvir, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype-4}}

It is on the World Health Organization's List of Essential Medicines.{{cite book | vauthors = ((World Health Organization)) | title = The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023) | year = 2023 | hdl = 10665/371090 | author-link = World Health Organization | publisher = World Health Organization | location = Geneva | id = WHO/MHP/HPS/EML/2023.02 | hdl-access=free }}

On December 11, 2024 it was approved in Russia under the trade name Konesko for the treatment of chronic hepatitis C in adult patients (only in combination with sofosbuvir). In the pivotal clinical trial STORM-C-1, the majority of patients were infected with HCV genotypes 1 or 3. Data from this study in patients with HCV genotypes 2 and 6 are limited, and data on patients with genotypes 4 or 5 are not available.{{cite web |title=Konesko (ravidasvir) Film-coated Tablets. Full Prescribing Information |url=https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=1a0127c0-603e-4716-9e86-d737147373b2 |website=Russian State Register of Medicines |publisher=HTC «Chemrar» |access-date=14 March 2025 |language=ru}}

Preliminary clinical trial results were announced in Nov 2015.{{cite web | url = https://www.hepmag.com/article/PYRAMID-Sovaldi-ravidasvir-28085-1528583872 | title = Good Results for Sovaldi and Ravidasvir Treating Hepatitis C Genotype 4 | date = November 24, 2015 | work = Hepatitis Magazine }} In April 2017, press reports stated that a combination treatment involving ravidasvir and sofosbuvir had achieved a 97% clearup rate against hepatitis C in a clinical trial conducted in Malaysia and Thailand, and 100% in another conducted in Egypt.{{cite web | url = https://www.theguardian.com/science/2018/apr/12/non-profits-300-hepatitis-c-cure-as-effective-as-84000-alternative | vauthors = Kollewe J | title = Non-profit's $300 hepatitis C cure as effective as $84,000 alternative | work = The Guardian | date = 13 April 2018 }} It has been granted conditional registration by the National Pharmaceutical Regulatory Agency (NPRA) of Malaysia.{{Cite web|title=List of new products approved by the National Pharmaceutical Regulatory Agency (NPRA) of Malaysia|url=https://www.npra.gov.my/easyarticles/images/users/1047/Produk-yang-diluluskan-dalam-DCA-358-4-Jun-2021.pdf}}{{Cite web|date=2021-06-14|title=First hepatitis C treatment developed through South-South cooperation registered in Malaysia {{!}} DNDi|url=https://dndi.org/press-releases/2021/first-hepatitis-c-treatment-developed-through-south-south-cooperation-registered-in-malaysia/|access-date=2021-08-10|website=dndi.org|language=en-GB}}